Immune checkpoint inhibitors (ICIs) improve outcomes in non‐small cell lung cancer (NSCLC) with high PD‐L1 expression, but biomarkers beyond PD‐L1 are limited. The gene discussed is CD274; the disease is non-small cell lung carcinoma.